A Cross-sectional, Retrospective Screening and Case-control Study Examining the Frequency of, and Risk Factors Associated With, Impulse Control Disorders in Parkinson's Disease Patients Treated With MIRAPEX® (Pramipexole) and Other Anti-parkinson Agents (DOMINION Study)
- NCT00617019
- Not Specified
- OBSERVATIONAL
Last updated: 2013-11-13
Purpose of Trial
The purpose is to explore the frequency of impulse control disorders in Parkinson's patients treated with different Parkinson's medications.
This study is for people with
Parkinson Disease
Inclusion Criteria:
Observation Criteria:
Male or female outpatients, aged 30 to 75 years of age, with idiopathic PD. Patients must be selected on the basis of a prospective recruitment plan documented at the site, with the objective of obtaining an unbiased representative sample.
Patients must have been treated with anti-parkinson medication for a period of one year or greater and demonstrated a treatment response, in the opinion of the Investigator.
Patients must be willing and able to comply with study procedures. Patients must be willing and able to give meaningful, written informed consent. This must be completed prior to beginning any study procedures, in accordance with GCP and local legislation.
Exclusion Criteria:
ELIGIBILITY
Gender: ALL
Age: 30+
Healthy Volunteers: No
36 Locations
Gilbert
248.619.01034 Neurological Physicians of Arizona
Arizona, United States
Scottsdale
248.619.01007 Mayo Clinic - Scottsdale
Arizona, United States
Sun City
248.619.01025 Sun Health Research Institute
Arizona, United States
Fresno
248.619.01018 Margolin Brain Institute
California, United States
Oxnard
248.619.01031 Pacific Neuroscience Medical Group, Inc.
California, United States
San Francisco
248.619.01016 San Francisco VA PD Research, Education, & Clinical Center
California, United States
Sunnyvale
248.619.01023 The Parkinson's Institute
California, United States
Englewood
248.619.01021 Boehringer Ingelheim Investigational Site
Colorado, United States
Danbury
248.619.01027 Associated Neurologists, P.C.
Connecticut, United States
New Haven
248.619.01013 Molecular NeuroImaging
Connecticut, United States
Boca Raton
248.619.01020 Parkinson's Disease and Movement Disorders of Boca Raton
Florida, United States
Gainesville
248.619.01009 University of Florida
Florida, United States
Atlanta
248.619.01035 Emory University
Georgia, United States
Augusta
248.619.01006 Medical College of Georgia
Georgia, United States
Chicago
248.619.01014 Northwestern University
Illinois, United States
Kansas City
248.619.01001 The University of Kansas Medical Center
Kansas, United States
Baltimore
248.619.01015 John Hopkins Hospital
Maryland, United States
Southfield
248.619.01029 Clinical Neuroscience Center
Michigan, United States
Minneapolis
248.619.01022 University of Minnesota
Minnesota, United States
Piscataway
248.619.01008 Robert Wood Johnson Medical School
New Jersey, United States
Albany
248.619.01030 Parkinson's Disease and Movement Disorders Center
New York, United States
Commack
248.619.01036 Parkinson's Disease and Mov. Disorders Center of Long Island
New York, United States
New York
248.619.01017 Weill Cornell medical College
New York, United States
Durham
248.619.01003 Duke University Medical Center
North Carolina, United States
Cleveland
248.619.01028 The Cleveland Clinic Foundation
Ohio, United States
Allentown
248.619.01004 Lehigh Valley Hospital
Pennsylvania, United States
Philadelphia
248.619.01010 Parkinson's Disease research, Education and Clinical Center
Pennsylvania, United States
Philadelphia
248.619.01011 University of Pennsylvania
Pennsylvania, United States
Philadelphia
248.619.01024 Thomas Jefferson Hospital
Pennsylvania, United States
Pittsburgh
248.619.01019 Boehringer Ingelheim Investigational Site
Pennsylvania, United States
Upland
248.619.01012 Parkinson's Disease and Movement Disorders Center
Pennsylvania, United States
Warwick
248.619.01005 NeuroHealth
Rhode Island, United States
Nashville
248.619.01033 Vanderbilt University Medical Center
Tennessee, United States
Dallas
248.619.01032 Neurology Spclst of Dallas, PA
Texas, United States
Houston
248.619.01002 Baylor College of Medicine
Texas, United States
Richmond
248.619.01026 Neurology/Southeast Parkinson's Disease
Virginia, United States
Primary Contact(s)
Boehringer Ingelheim
Data obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Learn more at
ClinicalTrials.gov